Latest Ventures
Cardiff University has an excellent track record of commercially exploiting the outcomes of its research. Forming a company to exploit University know-how or expertise is one of the routes available, and is managed through a close working relationship with Fusion IP. Licensing and royalty agreements, which enable businesses to use Cardiff research commercially, bring enormous benefits to a range of companies. Examples of recent successes are shown below along with current opportunities. If you are interested in obtaining further information please contact us.
Latest News
University's Anti-Viral Drug Acquired In £1.6bn takeover
Bristol-Myers Squibb secures rights to INX-189 through Inhibitex Buyout
Cymtox Wins Innovation Award 2011
Cymtox / BIOSI collaboration wins Innovation Award
Innovative Healthcare Solution: 'Hall Lock System'
Hall Lock product launched aiming to prevent wrong route administration
Breakthrough In Cancer Mutations: Detection & Causes
Novel technology for evaluating DNA damage offers potential for genotoxicity testing
EPSRC Follow-On Fund Success
Two major awards from EPSRC translational funds.
Spinout News
Asalus: 'Innervision' Set For Clinical Trials
Cardiff University spin-out to begin first 'in man' clinical trials for revolutionary smoke removal device
Mesuro Posts Record $1.25M Sales
Cardiff University spin-out nets record sales of Radio Frequency technology
New Spin-Out: DECIPHer IMPACT
Joint Cardiff / Bristol venture leads to anti-smoking spin-out
Medaphor Launches First Product: ScanTrainer
Fusion IP/Medaphor launch Medaphor's first product, the trans-vaginal ScanTrainer
Progenteq: Articular Stem-cell therapy
Progenteq is spun-out from BIOSI to develop innovative cartilage repair therapies
Recently Licensed Technologies
- Cardiff University Licensing Summary: Academic Year 2008/09
- Protide Technology Licensed To NuCana Biomed Ltd
Current Licensing Opportunities
For further information please contact the Technology Transfer Group